Reign Pharmaceuticals PCSIR - KLC products and prices in Pakistan
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Follow price changes 🔒 Company report (Pharma Pro)Private pharmaceutical manufacturer · Karachi · Pakistan
Karachi-based pharmaceutical manufacturer operating from the PCSIR Laboratories Complex and represented in DRAP registration-board records.
Reign Pharmaceuticals PCSIR - KLC products in Pakistan
Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd has 47 medicine presentations registered in Pakistan under 26 brands, covering 22 generic medicines. Most of its products are in Anti-infectives, Pain & musculoskeletal and Vitamins, minerals & nutrition. Its brands with the most registered strengths and packs are Renflox (Ciprofloxacin), Nuprin (Ibuprofen), REFTOX (Cefotaxime) and Renzith (Azithromycin). 47 products have an official DRAP price on MedInfoBase. See all 26 brands A to Z
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Reign Pharmaceuticals PCSIR-KLC (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- TBIC Building-1, PCSIR Laboratories Complex, Shahrah-e-Dr. Salim-uz-Siddiqui, Off University Road, Karachi, Pakistan
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 50%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
See where Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd. is priced against the market
44 of its products have like-for-like competitors. Pharma Pro shows how many are priced below, near or above the market median, the company's overall price position, and product-by-product examples.
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
🔒 3 more overlapping companies, with shared-generic detail, in Pharma Pro. Unlock
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| RAYFIX | Cefixime | 100 mg/5 mL | Suspension | 30ml | 088953 | PKR 285.13 | PKR 9.50/mL | 🔒 Pharma Pro |
| RAYFIX | Cefixime | 400 mg | Capsule | 5's | 088954 | PKR 564.16 | PKR 112.83/capsule | 🔒 Pharma Pro |
| RAYFIX DS | Cefixime | 200 mg/5 mL | Dry suspension | 30ml | 088952 | PKR 385.30 | PKR 12.84/mL | 🔒 Pharma Pro |
| RECOTAX | Ceftriaxone | 500 mg | Injection | 1's | 088948 | PKR 323.14 | PKR 323.14/vial/unit | 🔒 Pharma Pro |
| RECOTAX | Ceftriaxone | 1000 mg | Injection | 1's | 088949 | PKR 610.16 | PKR 610.16/vial/unit | 🔒 Pharma Pro |
| REFTOX | Cefotaxime | 500 mg | Injection | 1's | 088950 | PKR 159.25 | PKR 159.25/vial/unit | 🔒 Pharma Pro |
| REFTOX | Cefotaxime | 250 mg | Injection | 1's | 088951 | PKR 105.67 | PKR 105.67/vial/unit | 🔒 Pharma Pro |
| REFTOX | Cefotaxime | 1 g | Injection | 1's | 088955 | PKR 286.42 | PKR 286.42/vial/unit | 🔒 Pharma Pro |
All 26 Reign Pharmaceuticals PCSIR - KLC brands in Pakistan
- Andin Loratadine · 10 mg tablet, 5 mg/5 mL syrup
- C-Throcin Clarithromycin · 125 mg/5 mL suspension
- Dumol Paracetamol · 120 mg/5 mL syrup
- Folic Acid Folic acid · 5 mg tablet
- Gnate Artemether + Lumefantrine · 40 mg + 240 mg tablet
- Gnate DS Artemether + Lumefantrine · 80 mg + 480 mg tablet
- Largimox Moxifloxacin · 400 mg tablet
- Lesil Levofloxacin · 250 mg tablet, 500 mg tablet
- Loczole Fluconazole · 150 mg capsule
- Nuprin Ibuprofen · 100 mg/5 mL suspension
- OM-R Omeprazole enteric coated pellets · 20 mg capsule, 40 mg capsule
- RAYFIX Cefixime · 100 mg/5 mL suspension, 400 mg capsule
- RAYFIX DS Cefixime · 200 mg/5 mL suspension
- RECOTAX Ceftriaxone · 1000 mg injection, 500 mg injection
- REFTOX Cefotaxime · 1 g injection, 250 mg injection, 500 mg injection
- Reign's Ascorbic acid · 500 mg tablet
- Ren - C 1000 Ascorbic acid + Calcium carbonate + Calcium lactate + Calcium gluconate · 500 mg + 327 mg + 422 mg + 578 mg sachet
- Renchloro Chloroquine · 250 mg tablet, 50 mg/5 mL syrup
- Renflox Ciprofloxacin · 125 mg/5 mL suspension, 250 mg tablet, 250 mg/5 mL suspension
- Renflu Fluconazole · 150 mg tablet
- Renhydro Fate Hydroxychloroquine · 200 mg tablet
- Rentanic Ferrous sulfate + Folic acid · 150 mg + 0.5 mg tablet
- Renzith Azithromycin · 200 mg/5 mL suspension, 250 mg tablet, 500 mg tablet
- Rezo-lid Linezolid · 400 mg tablet, 600 mg tablet
- Sachets Nutrilyte Sodium chloride + Glucose + Potassium chloride + Trisodium citrate · 2.6 g + 13.5 g + 1.5 g + 2.9 g sachet
- Sachets Rapolyte Sodium chloride + Glucose + Potassium chloride + Trisodium citrate · 1.3 g + 6.75 g + 0.75 g + 1.45 g sachet
Reign Pharmaceuticals PCSIR - KLC: common questions
How many products does Reign Pharmaceuticals PCSIR - KLC have in Pakistan?
Reign Pharmaceuticals PCSIR - KLC (Pvt.) Ltd has 47 registered medicine presentations in Pakistan, sold under 26 brands and covering 22 generic medicines.
What are the main brands of Reign Pharmaceuticals PCSIR - KLC?
By number of registered strengths and packs, its largest brands are Renflox (Ciprofloxacin), Nuprin (Ibuprofen), REFTOX (Cefotaxime), Renzith (Azithromycin) and Andin (Loratadine). This is not a sales ranking.
Which therapy areas does Reign Pharmaceuticals PCSIR - KLC cover?
The most products are in Anti-infectives (31), Pain & musculoskeletal (5), Vitamins, minerals & nutrition (5), Respiratory & allergy (2) and Gastrointestinal & hepatology (2).
Where can I see Reign Pharmaceuticals PCSIR - KLC medicine prices?
Open any brand in the list above for its official DRAP price, pack sizes, price history and other brands of the same medicine.
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.